Anika Therapeutics Inc. Stock News

BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans

MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2023 Earnings Conference Call November 2, 2023 5:30 PM ET Company Participants Mark Namaroff - Vice President Investor Relations, ESG & Corporate Communicati

At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.

The heavy selling pressure might have exhausted for Anika (ANIK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r

Anika (ANIK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anika (ANIK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.20 per share a year ago.

BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans

Anika Therapeutics Inc. (NASDAQ:ANIK ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Mark Namaroff - Executive Director of IR & Corporate Communications Cheryl Blanchard

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.20 per share a year ago.

BEDFORD, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plan

Anika (ANIK) delivered earnings and revenue surprises of -54.55% and 3.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

With Americans being an optimistic bunch, the general assumption that the equities sector will rise following the ugly year in 2022 fundamentally bolsters several stocks to buy. However, it's importan